Voyager Therapeutics, Inc.

NASDAQ:VYGR

Biotechnology

Healthcare
$1.67 +2.35%

+$0.09 today

Market cap
$103.92M
Beta
1.25
P/E (TTM)
-1.9
EPS (TTM)
-$1.96
52W Low $2.83High $5.55

Volume 0.84M

Average 0.54M

VYGR Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Voyager Therapeutics, Inc.NASDAQ: VYGR

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses declines year over year

Q1 FY2026 other income / expenses of $2.35M fell 36.7% year over year, ahead of the -38.7% change in trailing-twelve-month other income / expenses. Sequentially, it fell 6.7% from the prior quarter. Over 3 fiscal years it compounded at +40.3% a year.

Context

  • Other income / expenses amounted to 30.4% of revenue in FY2025, up 6.7 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -36.7% holds above the trailing-twelve-month pace of -38.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.35M-6.7% QoQ
Last fiscal yearDec 2025
$12.27M-35.3% YoY
LTMMar 2026
$10.91M-38.7% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.7%——
1 year-35.3%——
3-year CAGR+40.3%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
12.27M USD
Year-over-year change
-35.3%
4-year CAGR
+50.0%

Other Income / Expenses vs competitors

How VYGR compares with its peers on the latest reported figures

  • VYGR's LTM Mar 2026 other income / expenses of $10.91M is the 5th highest of the 11 companies compared; the peer median is $10.6M.
  • Its year-over-year change of -38.7% is the 6th highest of 11, against a peer median of -39.3%.
  • Other income / expenses amounts to 29.9% of revenue for VYGR, versus a peer median of 31.5%.
VYGR Competitors Peer median
Other Income / Expenses for VYGR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$16.46M -3.2%——
HUMAHumacyte, Inc.LTM Mar 2026$16.3M -51.1%-2.8%808.4%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$14.02M -40.6%+13.7%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$13.26M -32.7%+71.0%231.0%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$10.91M -38.7%+40.3%29.9%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$10.66M -47.6%+36.1%4.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$10.54M -22.0%—23.2%
PYXSPyxis Oncology, Inc.LTM Mar 2026$5.52M -41.1%+30.8%39.8%
SGMTSagimet Biosciences Inc.LTM Mar 2026$5.23M -38.1%+119.1%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$460K +357.0%——
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$1.51M -146.9%+2.8%2.2%
Peer median (excluding VYGR) $10.6M-39.3%+30.8%31.5%

Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.42M40.91M250.01M80M40.37M
Cost of Revenue73.79M55.76M92.17M00
Gross Profit(36.37M)(14.86M)157.84M80M40.37M
Gross Margin-97.2%-36.3%63.1%100.0%100.0%
Research & Development73.79M60.76M92.17M127.37M134.67M
Selling, General & Admin37.25M30.98M35.82M35.92M37.54M
Operating Expenses37.25M35.98M35.82M163.29M172.22M
Depreciation & Amortization5.17M6.19M4.44M4.73M4.06M
EBITDA(66.03M)(39.65M)138.18M(59.61M)(115.52M)
EBITDA Margin-176.5%-96.9%55.3%-74.5%-286.1%
Operating Income(73.62M)(50.84M)122.01M(83.29M)(131.84M)
Operating Margin-196.8%-124.3%48.8%-104.1%-326.6%
Interest Income01.79M11.72M18.33M10.62M
Interest Expense00000
Other Income / Expenses2.42M4.45M11.72M18.95M12.27M
Income Before Tax(71.2M)(46.39M)133.74M(64.34M)(119.58M)
Pre-Tax Margin-190.3%-113.4%53.5%-80.4%-296.2%
Income Tax Expense016K1.41M665K144K
Net Income(71.2M)(46.41M)132.33M(65M)(119.72M)
Net Margin-190.3%-113.4%52.9%-81.3%-296.5%
EPS (Basic)(1.75)(1.21)3.08(1.13)(2.04)
EPS (Diluted)(1.75)(1.21)2.97(1.13)(2.04)
Weighted Avg Shares37.67M38.36M43.02M57.67M58.69M
Weighted Avg Shares (Diluted)37.67M38.36M44.57M57.67M58.69M

Voyager Therapeutics, Inc.

NASDAQ:VYGR

Intrinsic Alpha fair value

Locked

Current Price

$1.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.